Travere Therapeutics (TVTX) Interest & Investment Income (2013 - 2026)

Travere Therapeutics (TVTX) has 8 years of Interest & Investment Income data on file, last reported at $2.6 million in Q1 2026.

• Quarterly Interest & Investment Income fell 31.91% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 26.12% YoY) and the FY2025 annual result came in at $12.7 million, down 28.6% from the prior year.
• Interest & Investment Income steadied at $2.6 million in Q1 2026, from $2.6 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.2 million in Q4 2023 to a low of $278000.0 in Q1 2022.
• A 5-year average of $3.6 million and a median of $3.6 million in 2024 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1219.92% — and 2024, when it sank 46.94%.
• Tracing TVTX's Interest & Investment Income over 5 years: stood at $3.1 million in 2022, then soared by 129.6% to $7.2 million in 2023, then plunged by 46.94% to $3.8 million in 2024, then slumped by 31.7% to $2.6 million in 2025, then decreased by 0.31% to $2.6 million in 2026.
• The last three Interest & Investment Income figures came in at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.